Image For Activity Cover
Expert Guidance on GLP-1 Receptor Agonists in Type 2 Diabetes: A Case-Based Approach
Course Description

This is a one-hour on-demand webinar focusing on current best practices in leveraging GLP-1 RA therapy in T2D management  with 2 ClinicalThought expert commentaries. This activity is in collaboration with our partner- Clinical Care Options (CCO).

Learning Objectives
Upon successful completion of the activities, participants should be better able to:
  • Apply recommendations from the latest ADA and AACE diabetes management guidelines regarding use of diabetes drugs in patients with high CV risk and/or renal disease
  • Consider the key clinical evidence from CV outcomes trials with GLP-1 RAs in management decisions for patients with T2D
  • Differentiate the pharmacokinetic/pharmacodynamic characteristics and side effect profiles of injection and oral GLP-1 RA products to optimize their use according to patient requirements and preferences
Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Endocrine Society and Clinical Care Options (CCO).

The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Endocrine Society has achieved Accreditation with Commendation.

AMA PRA Category 1 Credit
The Endocrine Society designates each activity in this course for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.

Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.

Maintenance of Certification (MOC) - if eligible
Successful completion of each CME activity in this course, which includes participation in the evaluation component, enables the participant to earn up to 1.00 points in the American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

For questions about content or obtaining CME credit, please contact the Endocrine Society at

Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the Endocrine Society. Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.


Vanita R. Aroda, MD
Director, Diabetes Clinical Research
Division of Endocrinology, Diabetes & Hypertension
Brigham and Women’s Hospital
Faculty, Harvard Medical School
Boston, MA

Arthi Thirumalai, MBBS
Assistant Professor
Division of Metabolism, Endocrinology and Nutrition
University of Washington
Seattle, WA

As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.

The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The following faculty reported  relevant financial relationships during the content development process for this activity: 

Vanita R. Aroda, MD: Consultant, Applied Therapeutics, Duke, Pfizer, Novo Nordisk, Sanofi;  Employee (Spouse), Merck, Janssen Research Support, Applied Therapeutics/Medpace, Eli Lilly, Premier/Fractyl, Novo Nordisk, Sanofi/Medpace

Arthi Thirumalai, MBBS: Investigator Grant, Novo Nordisk

The following SPC member who planned and reviewed content for this activity reported no relevant financial relationships:  Beret Anne Casey, MD

The following SPC Committee members reported financial relationships:

Andjela T. Drincic, MDAdvisory Board Member, Corcept
Sergio Fazio, MD, PhDConsultant, Amarin, Amgen, Akcea, Aegerion, Esperion, Novartis
Angela M. Leung, MDSpeaker, Medical Education Resources, MCE Conferences, ATA Board Member
Amy Rothberg, MDSpouse, consultant of Merck
Katherine Araque, MDSpeaker, Novo Nordisk; Advisory Board, Corcept

The Endocrine Society and CCO has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.

The following SPC members reported no relevant financial relationships: Lorena Alarcon-Casas Wright, MD, Neena Natt, MD; Kelly Lauter Roszko, MD, PhD; Deborah Sellmeyer, MD; Savitha Subramanian, MD; Soleymani Taraneh, MD; Steven Weitzman, MD

The Endocrine Society and CCO staff associated with the development of content for this activity reported no relevant financial relationships.

The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable


This educational activity is supported by an independent medical educational grant from Novo Nordisk, Inc.

Availability: Retired
Cost : FREE
Credit Offered:
No Credit Offered
     EndoCareers | Contact Us | Privacy Policy | Terms of Use CONNECT WITH US                
       © 2021 Copyright Endocrine Society. All rights reserved.
2055 L Street NW, Suite 600 | Washington, DC 20036      
 202.971.3636 | 888.363.6274
Powered By